Abstract
Hepatoblastoma is the most common primary malignant neoplasm of the liver in children. Improvements in chemotherapy and surgical techniques have increased survival rates for those with localized disease. The prognosis for patients with progressive or relapsed disease continues to be dismal. Complete resection by surgery or liver transplantation is necessary for cure. Few conventional chemotherapy agents have demonstrated activity in progressive or relapsed hepatoblastoma. Irinotecan has shown activity in relapsed and progressive hepatoblastoma. The efficacy of high-dose chemotherapy in this setting is unknown. Newer targeted agents that ‘selectively’ interfere with pathway targets involved in tumor growth and progression such as insulin-like growth factor, phosphatidylinositol 3-kinase (PI3K), Akt, and mammalian target of rapamycin (mTOR) are currently under development. Because of the rarity of hepatoblastoma, only a small minority of these agents will ever be evaluated in children with this disorder. Gene-directed therapy and immunotherapy have shown promising results in the preclinical setting, and should be investigated as future treatment options for advanced hepatoblastoma.
Similar content being viewed by others
References
Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006 Sep; 42 (13): 2115–23.
Li J, Thompson TD, Miller JW, et al. Cancer incidence among children and adolescents in the United States, 2001–2003. Pediatrics 2008 Jun; 121 (6): e1470–7
Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology — SIOPEL 2. Eur J Cancer 2004 Feb; 40 (3): 411–21.
Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002 Jul 1;95(1): 172–82
Zsiros J, Maibach R, Shafford E, et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: final results of the SIOPEL-3HR study. J Clin Oncol 2010 May 20; 28 (15): 2584–90.
Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009 Oct; 361 (17): 1662–70.
Malogolowkin MH, Katzenstein H, Krailo MD, et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. J Clin Oncol 2006 Jun 20; 24 (18): 2879–84.
Semeraro M, Brugieres L, Zsiros J. 41st Annual Conference of International Society of Paediatric Oncology SIOP 2009, Sao Paulo, Brazil, October 5–9, 2009. Pediatr Blood Cancer 2009 Nov; 53 (5): 701–915.
Black CT, Cangir A, Choroszy M, et al. Marked response to preoperative high-dose cis-platinum in children with unresectable hepatoblastoma. J Pediatr Surg 1991 Sep; 26 (9): 1070–3.
Douglass EC, Green AA, Wrenn E, et al. Effective cisplatin (DDP) based chemotherapy in the treatment of hepatoblastoma. Med Pediatr Oncol 1985; 13 (4): 187–90.
Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a Pediatric Oncology Group phase II study. J Clin Oncol 2002; 20 (16): 3438–44.
Neglia JP, Woods WG. Continuous-infusion doxorubicin in the treatment of primary hepatic malignancies of childhood. Cancer Treat Rep 1986 May; 70 (5): 655–7.
Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: a report from the Children’s Cancer Group and the Pediatric Oncology Group. J Clin Oncol 2000 Jul; 18 (14): 2665–75.
Malogolowkin MH, Katzenstein HM, Krailo M, et al. Redefining the role of doxorubicin for the treatment of children with hepatoblastoma. J Clin Oncol 2008 May 10; 26 (14): 2379–83.
Fuchs J, Bode U, von Schweinitz D, et al. Analysis of treatment efficiency of carboplatin and etoposide in combination with radical surgery in advanced and recurrent childhood hepatoblastoma: a report of the German Cooperative Pediatric Liver Tumor Study HB 89 and HB 94. Klin Padiatr 1999 Aug; 211 (4): 305–9.
Cacciavillano WD, Brugières L, Childs M, et al. Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group. Eur J Cancer 2004 Oct; 40 (15): 2274–9.
Katzenstein HM, Rigsby C, Shaw PH, et al. Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol 2002 Dec; 24 (9): 751–5.
Niwa A, Umeda K, Awaya T, et al. Successful autologous peripheral blood stem cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation. Pediatr Transplant 2009 Mar; 13 (2): 259–62.
Yoshinari M, Imaizumi M, Hayashi Y, et al. Peripheral blood stem cell transplantation for hepatoblastoma with microscopical residue: a therapeutic approach for incompletely resected tumor. Tohoku J Exp Med 1998 Mar; 184 (3): 247–54.
Perilongo G, Otte JB. Autologous peripheral blood stem-cell transplantation with a double-conditioning regimen for recurrent hepatoblastoma after liver transplantation: a valid therapeutic option or just too much. Pediatr Transplant 2009; Mar; 13 (2): 148–9.
Malogolowkin MH, Stanley P, Steele DA, et al. Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 2000 Mar; 18 (6): 1279–84.
Schnater JM, Aronson DC, Plaschkes J, et al. Surgical view of the treatment of patients with hepatoblastoma: results from the first prospective trial of the International Society of Pediatric Oncology Liver Tumor Study Group. Cancer 2002 Feb 15; 94 (4): 1111–20.
Matsunaga T, Sasaki F, Ohira M, et al. Analysis of treatment outcome for children with recurrent or metastatic hepatoblastoma. Pediatr Surg Int 2003 May; 19 (3): 142–6.
Feusner JH, Krailo MD, Haas JE, et al. Treatment of pulmonary metastases of initial stage I hepatoblastoma in childhood. Report from the Childrens Cancer Group. Cancer 1993 Feb 1; 71 (3): 859–64.
Meyers RL, Katzenstein HM, Krailo M, et al. Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma. J Pediatr Surg 2007 Dec; 42 (12): 2050–6.
Passmore SJ, Noblett HR, Wisheart JD, et al. Prolonged survival following multiple thoracotomies for metastatic hepatoblastoma. Med Pediatr Oncol 1995 Jan; 24 (1): 58–60.
Lockwood L, Heney D, Giles GR, et al. Cisplatin-resistant metastatic hepatoblastoma: complete response to carboplatin, etoposide, and liver transplantation. Med Pediatr Oncol 1993; 21 (7): 517–20.
Miyamura T, Chayama K, Yoshida R, et al. Successful treatment of unresectable advanced hepatoblastoma: living liver transplantation after surgical removal of lung metastasis. Pediatr Transplant [online]. Available from URL: http://www.ncbi.nlm.nih.gov [Accessed 2011 Feb 23]
Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004; 42 (1): 74–83.
Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999 Jun; 17 (6): 1815–24.
Rodriguez-Galindo C, Radomski K, Stewart CF, et al. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 2000 Oct; 35 (4): 385–402.
Houghton PJ, Cheshire PJ, Hallman II JD, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36 (5): 393–403.
Ijichi O, Ishikawa S, Shinkoda Y, et al. Response of heavily treated and relapsed hepatoblastoma in the transplanted liver to single-agent therapy with irinotecan. Pediatr Transplant 2006 Aug; 10 (5): 635–8.
Qayed M, Powell C, Morgan ER, et al. Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer 2010 May; 54 (5): 761–3.
Palmer RD, Williams DM. Dramatic response of multiply relapsed hepatoblastoma to irinotecan (CPT-11). Med Pediatr Oncol 2003 Jul; 41 (1): 78–80.
Guichard S, Arnould S, Hennebelle I, et al. Combination of oxaliplatin and irinotecan on human colon cancer cell lines: activity in vitro and in vivo. Anticancer Drugs 2001 Oct; 12 (9): 741–51.
Zeghari-Squalli N, Raymond E, Cvitkovic E, et al. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999 May; 5(5): 1189–96.
Beaty III O, Berg S, Blaney S, et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: a Children’s Oncology Group study. Pediatr Blood Cancer 2010 Sep; 55 (3): 440–5.
Stordal B, Pavlakis N, Davey R. Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. Cancer Treat Rev 2007 Jun; 33 (4): 347–57.
Fulbright JM, Huh W, Anderson P, et al. Can anthracycline therapy for pediatric malignancies be less cardiotoxic. Curr Oncol Rep 2010; Nov; 12 (6): 411–9.
Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001 Mar 1; 19 (5): 1444–54.
Safra T, Muggia F, Jeffers S, et al. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000 Aug; 11 (8): 1029–33.
Marina NM, Cochrane D, Harney E, et al. Dose escalation and pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in children with solid tumors: a pediatric oncology group study. Clin Cancer Res 2002 Feb; 8 (2): 413–8.
Gray SG, Eriksson T, Ekström C, et al. Altered expression of members of the IGF-axis in hepatoblastomas. Br J Cancer 2000 May; 82 (9): 1561–7.
Tomizawa M, Saisho H. Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol 2006 Oct 28; 12(40): 6531–5.
Hartmann W, Küchler J, Koch A, et al. Activation of phosphatidylinositol-3’-kinase/AKT signaling is essential in hepatoblastoma survival. Clin Cancer Res 2009 Jul 15; 15 (14): 4538–45.
Grotegut S, Kappler R, Tarimoradi S, et al. Hepatocyte growth factor protects hepatoblastoma cells from chemotherapy-induced apoptosis by AKT activation. Int J Oncol 2010 May; 36 (5): 1261–7.
Eichenmüller M, Gruner I, Hagl B, et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009 Feb; 49 (2): 482–90.
Ranganathan S, Tan X, Monga SPS. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol 2005 Aug; 8 (4): 435–47.
Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 2002 Jul 18; 21 (31): 4863–71.
Koch A, Denkhaus D, Albrecht S, et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 1999 Jan 15; 59 (2): 269–73.
Adesina AM, Lopez-Terrada D, Wong KK, et al. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 2009 Jun; 40 (6): 843–53.
Massoner P, Ladurner-Rennau M, Eder IE, et al. Insulin-like growth factors and insulin control a multifunctional signalling network of significant importance in cancer. Br J Cancer 2010 Nov 9; 103 (10): 1479–84.
Heidegger I, Pircher A, Klocker H, et al. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther 2011 Apr 15; 11 (8): 701–7.
Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 2010 Oct 15; 80 (8): 1115–24.
Ryan PD, Goss PE. The emerging role of the insulin-like growth factor pathway as a therapeutic target in cancer. Oncologist 2008 Jan; 13 (1): 16–24.
Kim SY, Toretsky JA, Scher D, et al. The role of IGF-1R in pediatric malignancies. Oncologist 2009 Jan; 14 (1): 83–91.
Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009 Aug 27; 28 (34): 3009–21.
Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs 2011 Apr; 20 (4): 507–18.
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002 Jul; 2 (7): 489–501.
Bjornsti M-A, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004 May; 4 (5): 335–48.
Jacinto E, Hall MN. Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol 2003 Feb; 4 (2): 117–26.
Wan X, Shen N, Mendoza A, et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1alpha/VEGF signaling. Neoplasia 2006 May; 8 (5): 394–401.
Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007 Jul 13; 282 (28): 20534–43.
Abraham RT. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol 2004; 279: 299–319.
Misawa A, Hosoi H, Tsuchiya K, et al. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN. Int J Cancer 2003 Mar 20; 104 (2): 233–7.
Hosoi H, Dilling MB, Liu LN, et al. Studies on the mechanism of resistance to rapamycin in human cancer cells. Mol Pharmacol 1998 Nov; 54 (5): 815–24.
Mondesire WH, Jian W, Zhang H, et al. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin Cancer Res 2004 Oct 15; 10 (20): 7031–42.
Geoerger B, Kerr K, Tang CB, et al. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res 2001 Feb 15; 61 (4): 1527–32.
Tan X, Apte U, Micsenyi A, et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology 2005 Jul; 129 (1): 285–302.
López-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009 Jun; 40 (6): 783–94.
McCrudden KW, Hopkins B, Frischer J, et al. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg 2003 Mar; 38 (3): 308–14; discussion 308–314
Glade Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 2008 Jan 20; 26 (3): 399–405.
Taylor M, Rössler J, Geoerger B, et al. New anti-angiogenic strategies in pediatric solid malignancies: agents and biomarkers of a near future. Expert Opin Investig Drugs 2010 Jul; 19 (7): 859–74.
Eder JP, Van de Woude GF, Boerner SA, et al. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 2009 Apr 1; 15 (7): 2207–14.
Peruzzi B, Bottaro DP. Targeting the c-Met signaling pathway in cancer. Clin Cancer Res 2006 Jun 15; 12 (12): 3657–60.
Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET. Trends Mol Med 2005; Jun; 11 (6): 284–92.
von Schweinitz D, Faundez A, Teichmann B, et al. Hepatocyte growth-factor-scatter factor can stimulate post-operative tumor-cell proliferation in childhood hepatoblastoma. Int J Cancer 2000 Jan 15; 85 (2): 151–9.
Armengol C, Cairo S, Fabre M, et al. Wnt signaling and hepatocarcinogenesis: the hepatoblastoma model. Int J Biochem Cell Biol 2011 Feb; 43 (2): 265–70.
Koch A, Waha A, Hartmann W, et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 2005 Jun 15; 11 (12): 4295–304.
Cairo S, Armengol C, De Reyniès A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008 Dec 9; 14 (6): 471–84.
Verkaar F, Zaman GJR. New avenues to target Wnt/b-catenin signaling. Drug Discov Today 2011; Jan; 16 (1–2): 16.
Yang L, Xie G, Fan Q, et al. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010 Jan 28; 29 (4): 469–81.
Ruizi Altaba A, Sánchez P, Dahmane N. Gli and hedgehog in cancer: tumours, embryos and stem cells. Nat Rev Cancer 2002 May; 2 (5): 361–72.
Oue T, Yoneda A, Uehara S, et al. Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg 2010 Feb; 45 (2): 387–92.
Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res 2007 Mar 1; 13 (5): 1383–8.
Teicher BA. Combinations of PARP, hedgehog and HDAC inhibitors with standard drugs. Curr Opin Pharmacol 2010 Aug; 10 (4): 397–404.
Muñoz-Gämez JA, Quiles-Pérez R, Ruiz-Extremera A, et al. Inhibition of poly (ADP-ribose) polymerase-1 enhances doxorubicin activity against liver cancer cells. Cancer Lett 2011 Feb 1; 301 (1): 47–56.
Tentori L, Leonetti C, Scarsella M, et al. Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 2006 Aug; 20 (10): 1709–11.
Miknyoczki SJ, Jones-Bolin S, Pritchard S, et al. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2003 Apr; 2 (4): 371–82.
Racz I, Tory K, Gallyas Jr F, et al. BGP-15-a novel poly(ADP-ribose) polymerase inhibitor-protects against nephrotoxicity of cisplatin without compromising its antitumor activity. Biochem Pharmacol 2002 Mar 15; 63 (6): 1099–111.
Rouleau M, Patel A, Hendzel MJ, et al. PARP inhibition: PARP1 and beyond. Nat Rev Cancer 2010 Apr; 10 (4): 293–301.
Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006 Oct; 5 (10): 835–44.
Heim M, Sharifi M, Hilger RA, et al. Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43–9006. Int J Clin Pharmacol Ther 2003 Dec; 41 (12): 616–7.
Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 2010 Nov 17; 304 (19): 2154–60.
Marsh A, Lo J, Cohen RA, et al. Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP. Pediatr Blood Cancer. Epub 2012 Apr 10
Powles T, Chowdhury S, Jones R, et al. Sunitinib and other targeted therapies for renal cell carcinoma. Br J Cancer 2011 Mar 1; 104 (5): 741–5.
Bukowski RM. Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma. Expert Rev Anticancer Ther 2010 May; 10 (5): 635–45.
Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011 Mar; 10 (3): 395–403.
Huynh H. Tyrosine kinase inhibitors to treat liver cancer. Expert Opin Emerg Drugs 2010 Mar; 15 (1): 13–26.
Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010 Sep 1; 80 (5): 550–60.
Sangro B, Mazzolini G, Ruiz M, et al. A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. Cancer Gene Ther 2010 Dec; 17 (12): 837–43.
Yang ZX, Wang D, Wang G, et al. Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol 2010 Apr; 136 (4): 625–30.
Sangro B, Mazzolini G, Ruiz J, et al. Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 2004 Apr 15; 22 (8): 1389–97.
Warmann SW, Fuchs J, Bitzer M, et al. Emerging gene-directed anti-tumor strategies against human hepatoblastoma. Expert Opin Biol Ther 2009 Sep; 9 (9): 1155–61.
Tomlinson GE, Douglass EC, Pollock BH, et al. Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer 2005 Oct; 44 (2): 177–84.
Weber RG, Pietsch T, von Schweinitz D, et al. Characterization of genomic alterations in hepatoblastomas: a role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000 Aug; 157 (2): 571–8.
Terracciano LM, Bernasconi B, Ruck P, et al. Comparative genomic hybridization analysis of hepatoblastoma reveals high frequency of X-chromosome gains and similarities between epithelial and stromal components. Hum Pathol 2003 Sep; 34 (9): 864–71.
Rainier S, Dobry CJ, Feinberg AP. Loss of imprinting in hepatoblastoma. Cancer Res 1995 May 1; 55 (9): 1836–8.
Honda S, Arai Y, Haruta M, et al. Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Br J Cancer 2008 Dec 2; 99 (11): 1891–9.
Warmann SW, Armeanu S, Heitmann H, et al. Optimizing vector application for gene transfer into human hepatoblastoma cells. Pediatr Surg Int 2006 Sep; 22 (9): 733–42.
Warmann SW, Fuchs J, Seitz G, et al. New trends in tumor biology: transfection of a human hepatoblastoma cell line with green fluorescent protein. J Pediatr Surg 2005 Apr; 40 (4): 653–57.
Warmann SW, Frank H, Heitmann H, et al. Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res 2008 Jan; 144 (1): 43–8.
Lieber J, Kirchner B, Eicher C, et al. Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr Blood Cancer 2010 Dec 1; 55 (6): 1089–95.
Lin Y-C, You L, Xu Z, et al. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther 2007 Apr; 18 (4): 379–86.
Warmann SW, Armeanu S, Heigoldt H, et al. Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro. Pediatr Blood Cancer 2009 Aug; 53 (2): 145–51.
Cattaneo R, Miest T, Shashkova EV, et al. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008 Jul; 6 (7): 529–40.
Chang J-F, Chen P-J, Sze DY, et al. Oncolytic virotherapy for advanced liver tumours. J Cell Mol Med 2009 Jul; 13 (7): 1238–47.
Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009 Jan; 9 (1): 64–71.
Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009; 330: 213–41.
Park B-H, Hwang T, Liu T-C, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008 Jun; 9 (6): 533–42.
Liu T-C, Hwang T, Park B-H, et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008 Sep; 16 (9): 1637–42.
Inaba H, Handgretinger R, Furman W, et al. Allogeneic graft-versus-hepatoblastoma effect. Pediatr Blood Cancer 2006 Apr; 46 (4): 501–5.
Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature 2001 May 17; 411 (6835): 385–9.
Lang P, Handgretinger R. Haploidentical SCT in children: an update and future perspectives. Bone Marrow Transplant 2008 Oct; 42 Suppl. 2: S54–9
Lang P, Pfeiffer M, Müller I, et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin Padiatr 2006 Dec; 218 (6): 321–6.
Lang P, Schumm M, Greil J, et al. A comparison between three graft manipulation methods for haploidentical stem cell transplantation in pediatric patients: preliminary results of a pilot study. Klin Padiatr 2005 Dec; 217 (6): 334–8.
Cho D, Shook DR, Shimasaki N, et al. Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 2010 Aug 1; 16 (15): 3901–9.
Pfeiffer M, Seitz G, Ruck P, et al. CD 155 is involved in NK-cell mediated lysis of human hepatoblastoma in vitro. Front Biosci 2011 Jun 1; 3: 1456–66.
Pfeiffer M, Schumm M, Feuchtinger T, et al. Intensity of HLA class I expression and KIR-mismatch determine NK-cell mediated lysis of leukaemic blasts from children with acute lymphatic leukaemia. Br J Haematol 2007 Jul; 138(1): 97–100.
Kim J-Y, Son Y-O, Park S-W, et al. Increase of NKG2D ligands and sensitivity to NK cell-mediated cytotoxicity of tumor cells by heat shock and ionizing radiation. Exp Mol Med 2006 Oct 31; 38 (5): 474–84.
Seitz G, Pfeiffer M, Fuchs J, et al. Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep 2010 Oct; 24 (4): 1067–72.
Jacobs JFM, Coulie PG, Figdor CG, et al. Targets for active immunotherapy against pediatric solid tumors. Cancer Immunol Immunother 2009 Jun; 58 (6): 831–41.
Jacobs JFM, Hoogerbrugge PM, van de Rakt MWMM, et al. Phenotypic and functional characterization of mature dendritic cells from pediatric cancer patients. Pediatr Blood Cancer 2007 Dec; 49 (7): 924–7.
Balza E, Carnemolla B, Mortara L, et al. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Int J Cancer 2010 Jul 1; 127 (1): 101–10.
Acknowledgments
No sources of funding were used to prepare this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Venkatramani, R., Furman, W.L., Fuchs, J. et al. Current and Future Management Strategies for Relapsed or Progressive Hepatoblastoma. Pediatr Drugs 14, 221–232 (2012). https://doi.org/10.2165/11597740-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11597740-000000000-00000